Literature DB >> 28087599

Long Noncoding RNA LINC00092 Acts in Cancer-Associated Fibroblasts to Drive Glycolysis and Progression of Ovarian Cancer.

Linjie Zhao1, Gaili Ji1, Xiaobing Le1, Chenlu Wang1, Lian Xu2, Min Feng2, Yaguang Zhang1, Huiliang Yang3, Yu Xuan1, Yanfei Yang1, Lingzi Lei1, Qilian Yang1, Wayne Bond Lau4, Bonnie Lau5, Yi Chen6, Xiangbing Deng6, Shaohua Yao1, Tao Yi1, Xia Zhao1, Yuquan Wei1, Shengtao Zhou7.   

Abstract

The majority of patients with epithelial ovarian cancer are diagnosed at a late stage when the peritoneal metastases exist; however, there is little knowledge of the metastatic process in this disease setting. In this study, we report the identification of the long noncoding RNA LINC00092 as a nodal driver of metastatic progression mediated by cancer-associated fibroblasts (CAF). Prometastatic properties of CAFs in vitro and in vivo were found to associate with elevated expression of the chemokine CXCL14. In clinical specimens, elevated levels of CXCL14 in CAFs also correlated with poor prognosis. Notably, CXCL14-high CAFs mediated upregulation of LINC00092 in ovarian cancer cells, the levels of which also correlated with poor prognosis in patients. Mechanistic studies showed that LINC00092 bound a glycolytic enzyme, the fructose-2,6-biphosphatase PFKFB2, thereby promoting metastasis by altering glycolysis and sustaining the local supportive function of CAFs. Overall, our study uncovered a positive feedback loop in the metabolism of CXCL14-positive CAFs and ovarian cancer cells that is critical for metastatic progression. Cancer Res; 77(6); 1369-82. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28087599     DOI: 10.1158/0008-5472.CAN-16-1615

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  69 in total

1.  Pharmacological activation of estrogen receptor beta augments innate immunity to suppress cancer metastasis.

Authors:  Linjie Zhao; Shuang Huang; Shenglin Mei; Zhengnan Yang; Lian Xu; Nianxin Zhou; Qilian Yang; Qiuhong Shen; Wei Wang; Xiaobing Le; Wayne Bond Lau; Bonnie Lau; Xin Wang; Tao Yi; Xia Zhao; Yuquan Wei; Margaret Warner; Jan-Åke Gustafsson; Shengtao Zhou
Journal:  Proc Natl Acad Sci U S A       Date:  2018-03-28       Impact factor: 11.205

2.  Long intergenic noncoding RNA LINC00284 knockdown reduces angiogenesis in ovarian cancer cells via up-regulation of MEST through NF-κB1.

Authors:  Zhengyi Ruan; Dong Zhao
Journal:  FASEB J       Date:  2019-10-01       Impact factor: 5.191

3.  Long non-coding RNAs in ovarian cancer: expression profile and functional spectrum.

Authors:  Selin Oncul; Paola Amero; Cristian Rodriguez-Aguayo; George A Calin; Anil K Sood; Gabriel Lopez-Berestein
Journal:  RNA Biol       Date:  2019-12-17       Impact factor: 4.652

4.  Long non-coding RNA TIRY promotes tumor metastasis by enhancing epithelial-to-mesenchymal transition in oral cancer.

Authors:  Nuo Jin; Nianqiang Jin; Wenhuan Bu; Xing Li; Lili Liu; Zilin Wang; Jin Tong; Dechao Li
Journal:  Exp Biol Med (Maywood)       Date:  2020-02-26

5.  LncRNA-NBAT-1 modulates esophageal cancer proliferation via PKM2.

Authors:  Bo Zhao; Peng Cao; Shan Hu; Fan Li; Kangle Kong; Yukun Zu
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

6.  miR-17-5p-CXCL14 axis related transcriptome profile and clinical outcome in diffuse gliomas.

Authors:  Ailiang Zeng; Jianxin Yin; Zheng Wang; Chuanbao Zhang; Rui Li; Zhuoran Zhang; Wei Yan; Yongping You
Journal:  Oncoimmunology       Date:  2018-09-11       Impact factor: 8.110

Review 7.  Long non-coding RNAs involved in cancer metabolic reprogramming.

Authors:  Hui Liu; Junyun Luo; Siyu Luan; Chongsheng He; Zhaoyong Li
Journal:  Cell Mol Life Sci       Date:  2018-10-19       Impact factor: 9.261

Review 8.  The involvement of lncRNAs in the development and progression of pancreatic cancer.

Authors:  Li Duguang; He Jin; Qian Xiaowei; Xu Peng; Wang Xiaodong; Li Zhennan; Qian Jianjun; Yao Jie
Journal:  Cancer Biol Ther       Date:  2017-11-27       Impact factor: 4.742

Review 9.  Turning foes to friends: targeting cancer-associated fibroblasts.

Authors:  Xueman Chen; Erwei Song
Journal:  Nat Rev Drug Discov       Date:  2019-02       Impact factor: 84.694

Review 10.  Emerging role of metabolic reprogramming in tumor immune evasion and immunotherapy.

Authors:  Chunmei Fan; Shanshan Zhang; Zhaojian Gong; Xiayu Li; Bo Xiang; Hao Deng; Ming Zhou; Guiyuan Li; Yong Li; Wei Xiong; Zhaoyang Zeng; Xiaoling Li
Journal:  Sci China Life Sci       Date:  2020-08-17       Impact factor: 6.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.